MORGAN STANLEY

Holdings History for UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

Symbol: URGN on Nasdaq
Investment type: Equity - Shares of Stock
Class: Ordinary Shares, par value NIS 0.01 per share
Latest Disclosed Ownership: 753K shares
Security Ownership: 1.8%

Shares, Excluding Options vs Price

Value, Excluding Options

Morgan Stanley ownership in UroGen Pharma Ltd. Ordinary Shares, par value NIS 0.01 per share (URGN)

2025-02-05 - Morgan Stanley has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 753K shares of UroGen Pharma Ltd. Ordinary Shares, par value NIS 0.01 per share (URGN). This represents 1.8% percent ownership of the company.

Reporting Name	Ownership %	Change	Value $	Shares owned	Change	Activity %	Price	Form	Report date	Filed at
Morgan Stanley	1.8%		$8.33M	753K			$11.06	13G/A	12/31/2024	5 Feb 2025 10:09:20

Holdings date	Weight	Change	Value $	Shares	Change	Activity %	Price	All Holders
12/31/2024	0%	0%	$8.17M	767K	-1,414,164	-64.8%	$10.65	Q4 2024
9/30/2024	0%	+0%	$27.7M	2.18M	+342,758	+18.6%	$12.70	Q3 2024
6/30/2024	0%	+0%	$30.9M	1.84M	+1,448,157	+371%	$16.78	Q2 2024
6/30/2024			$23.00	1			$23.00^*	Q2 2024
3/31/2024	0%		$5.86M	391K			$15.00^*	Q1 2024
3/31/2024	0%		$5.86M	391K			$15.00	Q1 2024
12/31/2023	0%		$6.83M	455K			$15.00	Q4 2023
9/30/2023	0%	+0%	$1.56M	111K	+48,174	+76.5%	$14.01	Q3 2023
6/30/2023	0%	0%	$652K	63K	-80,506	-56.1%	$10.35	Q2 2023
3/31/2023	0%	+0%	$1.33M	143K	+94,310	+192%	$9.24	Q1 2023
12/31/2022	0%	+0%	$436K	49.1K	+4,139	+9.2%	$8.87	Q4 2022
9/30/2022	0%	0%	$376K	45K	-38,266	-46%	$8.35^*	Q3 2022
6/30/2022	0%	+0%	$681K	83.3K	+43,383	+109%	$8.18^*	Q2 2022
3/31/2022	0%	+0%	$349K	39.9K	+17,531	+78.4%	$8.75^*	Q1 2022
12/31/2021	0%	0%	$214K	22.4K	-21,340	-48.8%	$9.57^*	Q4 2021
9/30/2021	0%	0%	$734K	43.7K	-29,898	-40.6%	$16.80	Q3 2021
6/30/2021	0%	+0%	$1.13M	73.6K	+72,367	+5869%	$15.29	Q2 2021
3/31/2021	0%	0%	$24K	1.23K	-15,945	-92.8%	$19.46	Q1 2021
12/31/2020	0%	+0%	$310K	17.2K	+13,495	+366%	$18.05	Q4 2020
9/30/2020	0%	0%	$71K	3.68K	-87,348	-96%	$19.28	Q3 2020
6/30/2020	0%	+0%	$2.38M	91K	+87,825	+2739%	$26.11	Q2 2020
3/31/2020	0%	0%	$57K	3.21K	-24,803	-88.6%	$17.78	Q1 2020
12/31/2019	0%	+0%	$935K	28K	+17,832	+175%	$33.38	Q4 2019
9/30/2019	0%	+0%	$242K	10.2K	+4,759	+87.8%	$23.78	Q3 2019
6/30/2019	0%	0%	$194K	5.42K	-19,505	-78.3%	$35.81	Q2 2019
3/31/2019	0%	+0%	$920K	24.9K	+9,856	+65.4%	$36.91	Q1 2019
12/31/2018	0%	0%	$649K	15.1K	-14,823	-49.6%	$43.07	Q4 2018
9/30/2018	0%	0%	$1.41M	29.9K	-6,155	-17.1%	$47.24	Q3 2018
6/30/2018	0%	+0%	$1.79M	36K	+7,188	+24.9%	$49.77	Q2 2018
3/31/2018	0%	0%	$1.43M	28.9K	-4,555	-13.6%	$49.69	Q1 2018
12/31/2017	0%	+0%	$1.24M	33.4K	+9,756	+41.2%	$37.20	Q4 2017
9/30/2017	0%	+0%	$746K	23.7K	+23,656	NEW	$31.54	Q3 2017

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.